SK Capital Partners, a New York-based private investment firm, acquired Apotex Pharmaceutical Holdings, a Canadian pharmaceutical company.
The amount of the deal – closing of which is subject to the satisfaction of customary regulatory conditions – was not disclosed. RBC Capital Markets, The Bank of Nova Scotia, HSBC and Truist Securities are providing committed financing in support of the transaction.
With the acquisition, SK Capital will be supporting Apotex’s next phase of growth and continued innovation.
Led by CEO Jeff Watson, Apotex is a pharmaceutical company that produces medicines for patients around the world. Its employs nearly 8,000 people worldwide in manufacturing, R&D, and commercial operations. It exports to more than 100 countries and territories and operates in more than 45 countries, with presence in Canada, the United States, Mexico, and India.
FinSMEs